Neuroblastoma arises from sympathoadrenal progenitors of the neural crest and expression of the neurotrophin receptor TrkB and its ligand, brain-derived neurotrophic factor (BDNF), is correlated with poor prognosis. Although activated TrkB signaling promotes a more aggressive phenotype in established neuroblastoma cell lines, whether TrkB signaling is sufficient to transform neural crest-derived cells has not been investigated. To address the role of TrkB signaling in malignant transformation, we removed two immunoglobulin-like domains from the extracellular domain of the full-length rat TrkB receptor to create a DIgTrkB that is constitutively active. In the pheochromocytoma-derived cell line PC12, DIgTrkB promotes differentiation by stimulating process outgrowth; however, in the rat neural crest-derived cell line NCM-1, DIgTrkB signaling produces a markedly transformed phenotype characterized by increased proliferation, anchorage-independent cell growth, anoikis resistance and matrix invasion. Furthermore, expression of DIgTrkB leads to the upregulation of many transcripts encoding cancer-associated genes including cyclind1, twist1 and hgf, as well as downregulation of tumor suppressors such as pten and rb1. In addition, DIgTrkB NCM-1 cells show a 21-fold increase in mRNA for MYCN, the most common genetic marker for a poor prognosis in neuroblastoma. When injected into NOD SCID mice, control GFP NCM-1 cells fail to grow whereas DIgTrkB NCM-1 cells form rapidly growing and invasive tumors necessitating euthanasia of all mice by 15 days post injection. In summary, these results indicate that activated TrkB signaling is sufficient to promote the formation of a highly malignant phenotype in neural crest-derived cells.
INTRODUCTION
Neuroblastoma, a pediatric malignancy arising from sympathoadrenal precursors from the neural crest, is a cancer typified by its heterogeneity of disease. Disease course in neuroblastoma can range anywhere from patients presenting with metastatic disease that will spontaneously regress with support treatment alone (stage 4S), to localized favorable tumors and to cases of aggressive neuroblastoma, in which children will often relapse following treatment despite the most intensive chemo-and adjuvant therapy. 1 This heterogeneity in neuroblastoma tumor properties is correlated with a number of different factors including Trk receptor expression. 2 Trk receptors are important in normal sympathetic development; for example, TrkA, the high affinity receptor for nerve growth factor (NGF), promotes targetdependent survival of sympathetic neurons by preventing programmed cell death 3, 4 and neuroblastoma tumors that express TrkA have a favorable prognosis. 5 In contrast, many MYCN-amplified, poor prognosis neuroblastomas express TrkB, resulting in tumors that are often highly aggressive and eventually fatal. 6 As TrkB promotes plasticity, differentiation and survival of primary neurons, the aggressive phenotype correlated with TrkB expression was puzzling; however, we discovered that TrkB is transiently expressed in sympathetic progenitors prior to the onset of TrkA expression, and when stimulated with BDNF, the TrkB-expressing cells proliferate in cell culture 7, 8 and in vivo (Straub and Nishi, unpublished observations ).
An important question is whether TrkB expression is a marker of poor prognosis, or whether active TrkB signaling is directly responsible for the aggressive nature of poor prognosis neuroblastoma. Supporting a causal role for TrkB signaling, concomitant expression of full-length TrkB and BDNF leads to autocrine signaling that enhances tumor cell survival and invasiveness, 9 whereas expression of a truncated TrkB isoform lacking the tyrosine kinase domain is commonly found in more benign and differentiated tumors such as ganglioneuroblastomas. 10 Furthermore, treatment of TrkB-expressing SMS-KCN neuroblastoma cells with BDNF enhances cell survival in serum-free media. 11 Similarly, BDNF treatment of SH-SY5Y cells either transfected with TrkB or induced to express TrkB by retinoic acid have enhanced survival in conditions of limited growth factors, 9, 12 increased resistance to chemotherapeutics, [13] [14] [15] increased production of angiogenic factors 16, 17 and enhanced invasion. 9 Therefore, TrkB signaling contributes to the aggressiveness of poor prognosis neuroblastoma, but it is still unknown whether TrkB signaling alone can transform cells of the neural crest lineage.
In order to determine if constitutively active TrkB signaling is sufficient to transform cells, we created a mutant form of the TrkB receptor by removal of two immunoglobulin-like ligand-binding domains in the extracellular portion of the receptor. This construct is constitutively active and when stably transfected into a normal neural crest-derived cell line NCM-1, it promotes a highly malignant phenotype in vitro and in vivo.
RESULTS

Removal of two immunoglobulin-like domains renders TrkB constitutively active
Previous studies have shown the TrkA tyrosine kinase receptor can be rendered constitutively active by removal of the two immunoglobulin-like domains in the extracellular region of the receptor. 18 Therefore, we created a similar construct (DIgTrkB; Supplementary Figure S1 ) and stably transfected HEK293 cells with DIgTrkB and full-length wild-type (WT) TrkB. Expression of both types of receptor were confirmed (Figure 1a ). A marked increase of phosphorylated Erk 1/2 is observed when WT TrkB HEK293 cells are treated with BDNF and in DIgTrkB HEK293 cells (Figure 1a ), albeit at significantly lower levels when compared with the BDNF-stimulated WT TrkB (Figure 1b ). Therefore, we tested whether this level of constitutive signaling by DIgTrkB was sufficient to promote downstream biological effects.
DIgTrkB promotes neurite outgrowth in PC12 cells PC12 cells are a well-known model of NGF-induced neuronal differentiation via TrkA, 19, 20 and TrkB-transfected PC12 cells differentiate in response to BDNF. 21 PC12 cells were transiently transfected with DIgTrkB or GFP control construct, and 2 days later, treated with or without 7sNGF (1 mg/ml). After 6 days, the cells were fixed and stained for either TrkB or GFP to identify the transfected cells. Cells transfected with DIgTrkB show a six-fold increase in the number of neurite-bearing cells over GFPtransfected cells in the absence of NGF (Figures 2a-c) . The DIgTrkB-induced neurite outgrowth is equivalent to that of NGF through TrkA as there is no difference in the number of neurite-bearing cells between DIgTrkB or GFP-transfected cells in the presence of NGF ( Figure 2d ).
DIgTrkB enhances proliferation in the neural crest-derived cell line NCM-1 NCM-1 is an immortalized, but normal multipotent cell line with the ability to generate sympathoadrenal precursors. 22 To determine if constitutive TrkB signaling promotes proliferation or differentiation in NCM-1 cells, we transfected cells with DIgTrkB using a PiggyBac transposase/transposon vector (pmGENIE-3) that integrates the desired insert into the host chromosome followed by inactivation of the transposase. 23 Stable DIgTrkB NCM-1 transfectants grow to confluency more rapidly than nontransfected (CONT) NCM-1 cells. To quantify this apparent increase in proliferation, the cells were counted after various times in cell culture by measuring uptake of the vital fluorescent dye calcein AM. 24 We noted a 2.5-fold increase in cell number after 4 days in DIgTrkB NCM-1 cells compared with CONT NCM-1 cells (Figure 3a ). While constitutively active TrkA is transforming, fulllength (WT) TrkA plus NGF promotes differentiation; 25 therefore, we compared the growth rate of WT TrkB NCM-1 cells with or without BDNF. As seen in Figure 3b , the growth rate of WT TrkB NCM-1 cells is enhanced by the presence of BDNF. Thus, ligandinduced activation of WT TrkB also enhances proliferation as does the DIgTrkB. Additionally, treatment with the pan-Trk kinase inhibitor K252a abolished DIgTrkB-mediated proliferation, resulting in calcein AM fluorescence equivalent to that in CONT NCM-1 cells, (Figure 3c ) suggesting that TrkB kinase activity is required for the observed enhanced proliferation. In order to confirm that the enhanced proliferation did not arise from an insertion of our construct into a tumor suppressor, five additional parent lines were established that all show a significant increase in cell number after 4 days in vitro (Supplementary Figure S2 ). Further, supporting the enhanced proliferation, western blot analysis for the proliferation markers, phosphorylated histone H3 and cyclin D1 Figure 1 . DIgTrkB is expressed and is constitutively active. HEK293 cells were stably transfected with either a WT or DIgTrkB construct. Cells were then treated with or without BDNF (100 ng/ml) and protein was isolated. Figure S3 ). Therefore, constitutive signaling through DIgTrkB promotes an enhanced rate of growth in CONT NCM-1 cells.
DIgTrkB transforms NCM-1 cells
Enhanced proliferation alone is not sufficient to consider a cell transformed. Another feature common to transformed cells is the loss of requirement for attachment to a surface to divide, a property known as anchorage-independent cell growth. 26 To determine if DIgTrkB expression confers anchorage-independent cell growth to NCM-1 cells, the cells were cultured suspended in soft agar ( Figure 4 ). Although CONT NCM-1 cells failed to grow colonies in soft agar regardless of the presence of BDNF (Figures 4a, b ), DIgTrkB NCM-1 cells grow many colonies whether or not BDNF is present (Figures 4c, d, g) . In contrast, very few colonies are formed by WT TrkB cells in the absence of BDNF (Figures 4e, g ), but many are formed when WT TrkB NCM-1 cells are stimulated by BDNF (Figures 4f, g) . Interestingly, the number of colonies formed mirrored the level of phospho-ERK activation (compare Figures 1b with 4g ). Furthermore, although DIgTrkB NCM-1 cells formed fewer colonies, the colonies that formed appeared larger than those formed by WT TrkB in the presence of BDNF (compare Figures 4d with 4f ).
Another feature related to anchorage-independent growth is the ability of transformed cells to survive when detached from the cell surface. 27 Normally, when cells grown in culture detach, they undergo anoikis, or detachment-induced apoptosis. To determine if DIgTrkB allows NCM-1 cells to become anoikis-resistant, the number of live cells in the medium collected from transfected and untransfected cells was quantified ( Figure 4h ). We observed a four-fold increase in the number of live cells in the media from DIgTrkB NCM-1 cultures compared with CONT NCM-1 (Po0.05, Figure 4d ), indicating that DIgTrkB promotes anoikis resistance in NCM-1 cells.
Another important characteristic of malignant transformation is the ability of cells to migrate to and invade surrounding tissues and blood vessels. To investigate whether DIgTrkB expression enhances migration and invasion, we used a radial migration assay known as 'the donut assay'. 28 In this assay, cells are limited to a restricted area by a silicone donut. Following donut removal, the number of cells migrating radially from the confined area are quantified. Neural crest cells are intrinsically migratory, as during development they must migrate from the neural tube to their final locations throughout the body. In light of this, we did not find any significant difference in the total number of migrating cells outside the originally confined area after 24 h (Figures 5a-c, e-g, j). However, there is a significant increase in the area within which migrated cells could be found, indicating DIgTrkB NCM-1 cells migrate farther compared with WT NCM-1 cells (Figures 5d, h-i).
To investigate invasion, a layer of crude extracellular matrix (matrigel) was overlaid on the cells. Although addition of matrigel leads to a reduction in the number of cells traveling outside the originally confined area for both cell types (Figure 5j vs 5t), DIgTrkB NCM-1 cells have an enhanced ability of invading the extracellular matrix, marked by a 2.5-fold increase in the number of cells invading after 24 h (Figures 5k-r, t). Furthermore, DIgTrkB NCM-1 cells invade farther into the matrigel as indicated by a 2.5fold increase in the total area invaded by DIgTrkB NCM-1 cells compared with CONT NCM-1 (Figures 5k-r, s).
DIgTrkB enhances cancer-related gene expression in NCM-1 cells
To identify genes contributing to the transformed phenotype in DIgTrkB NCM-1 cells, we analyzed transcripts using a targeted quantitative PCR (qPCR) array of cancer pathway genes (full table of genes analyzed is in the Supplementary Materials). This analysis revealed that DIgTrkB increases transcript levels for a number of tumor-promoting genes (Table 1) , as well as decreases in expression of tumor suppressors ( Table 2) . Consistent with the enhanced proliferation of DIgTrkB NCM-1 cells, we detected a 436fold increase in transcripts levels as well as significantly enhanced protein levels (Supplementary Figure S3 ) for the cell cycle regulatory gene cyclind1. Furthermore, upregulation of twist1 (39-fold) and hepatocyte growth factor (hgf, 29-fold), two genes known to have important roles in promoting invasion and metastasis, 29, 30 is consistent with the enhanced invasive capacity of DIgTrkB NCM-1 cells. Moreover, expression of DIgTrkB in NCM-1 cells significantly downregulates expression of the tumor suppressors pten ( À 1.71-fold) and rb1 ( À 1.77-fold). Therefore, the RNA expression profile of DIgTrkB NCM-1 cells is consistent with the highly transformed phenotype of the cells.
An important marker of poor prognosis in human neuroblastoma tumors is the amplified expression of MYCN. To determine if the transformation of NCM-1 cells by DIgTrkB influences MYCN, we compared transcript levels in CONT and DIgTrkB NCM-1 cells by qPCR. We found a 21-fold increase in MYCN levels in DIgTrkB NCM-1 cells compared with CONT NCM-1 cells (Po0.01). In contrast, although NCM-1 cells were immortalized by the use of a retroviral vector carrying vmyc, the levels of myc observed with the qPCR array were very low and did not differ between CONT-and DIgTrkB NCM-1 cells (see Supplementary Material regarding the gene list and qPCR array signals observed for each gene).
DIgTrkB NCM-1 cells form rapidly growing and aggressive tumors in vivo
To determine if DIgTrkB expression would enhance the ability of NCM-1 cells to form tumors in vivo, NOD-SCID mice were injected subcutaneously with 10 6 DIgTrkB or GFP NCM-1 cells suspended in matrigel. One week following injection, tumors became palpable in mice injected with DIgTrkB NCM-1 cells (Figure 6a, Po0.01) , and all DIgTrkB NCM-1-injected mice were killed by 15 days post injection due to tumor burden ( Figure 6b ). GFP NCM-1-injected mice remained tumor-free throughout the experiment ( Figure 6 ). Monitoring tumor size daily, DIgTrkB NCM-1 tumors grew extremely rapidly, measuring an estimated 8 cm3 by 2 weeks after injection, whereas GFP NCM-1 cells failed to grow (Figure 6c ). Upon removal, DIgTrkB NCM-1 cell tumors were extremely large and heavily vascularized with an average wet weight of 4.5 g (Figures 6e and f) . Not only do DIgTrkB tumors grow at a rapid pace, these tumors are also highly invasive, invading the vertebrae and compressing the spine resulting in bilateral hind limb paralysis in one mouse only 10 days following injection (Figures 6g and h) . Tumor tissue contains many closely packed cells with scant cytoplasm and little extracellular stroma, reminiscent of aggressive, poor prognosis neuroblastoma (Figure 6d ). Furthermore, a separate injection of only 100 cells formed tumors in 3/3 mice within 21 days, demonstrating that DIgTrkB NCM-1 cells are highly tumorigenic. Therefore, constitutive TrkB signaling is sufficient to transform the neural crestderived cell line NCM-1 into highly aggressive tumor cells in vivo.
DISCUSSION
In this study, we provide evidence that constitutive TrkB signaling is sufficient to transform a neural crest cell line into a carcinogenic phenotype marked by an enhancement of proliferation, anchorage-independent cell growth, anoikis resistance, migration and invasion, and upregulation of tumor promoter genes. The enhanced rate of proliferation and anchorage-independent cell growth was also observed when full-length TrkB was stimulated with BDNF in the same cell line. The isolation of the DIgTrkB NCM-1 cell line allowed us to test the behavior of these cells in vivo, and they displayed highly aggressive, tumorigenic behavior when injected subcutaneously. Taken together, our data suggest that aberrant TrkB signaling in the developing sympathoadrenal lineage may be sufficient to promote neuroblastoma formation. The involvement of Trk receptors in cancer is complex. The first Trk, for 'tropomyosin-receptor kinase', was isolated from a colon carcinoma, and resulted from the fusion of a truncated tropomyosin with the tyrosine kinase domain of a receptor that rendered the kinase constitutively active. 31 This kinase domain was subsequently discovered to belong to TrkA, the high affinity receptor for NGF. 20 In neuroblastomas, activation of full-length TrkA slows the rate of proliferation and promotes differentiation, 25 In contrast, the TrkB receptor, the highaffinity receptor for BDNF, enhances proliferation and anchorageindependent cell growth in many cell lines [32] [33] [34] and enhances invasion in a number of cancer-derived lines including neuroblastoma, 9, 29, 35 colon cancer, 36 head and neck squamous cell carcinoma 37 and non-small cell lung cancer. 38 TrkB also enhances in vivo tumor growth in neuroblastoma 39 and transitional cell carcinoma. 40 However, none of these studies have determined whether TrkB signaling in normal neural crestderived cells is sufficient to promote an aggressive, fully transformed phenotype. Constitutively activated TrkB in NCM-1 cells highly upregulates many genes also seen in poor prognosis neuroblastoma. CYCLIND1 is selectively amplified in poor prognosis neuroblastoma tumors, 41 as is TWIST1, which is expressed in 100% (7/7) of MYCNamplified tumors, but only 11% (2/18) of non-MYCN-amplified tumors. 42 In MYCN-amplified neuroblastoma cell lines, TWIST1 expression ranged from 16-164-fold to that of non-MYCNamplified lines, levels consistent with the 39-fold increase in twist1 expression we observe here in DIgTrkB NCM-1 cells. Suggesting a specific cooperation of TWIST1 and MYCN in neuroblastoma, TWIST1 inhibits expression of the tumor suppressor P53, which allows MYCN-amplified tumors, and in the case of our study, DIgTrkB NCM-1 cells, to escape P53-dependent apoptosis. In this study, we also observed a 29-fold upregulation of hgf together with a 1.5-fold upregulation of the HGF receptor c-met in DIgTrkB NCM-1 cells. Increased c-Met signaling is a common occurrence in many types of cancer, [43] [44] [45] [46] [47] and it has also been observed in neuroblastoma. 29 DIgTrkB NCM-1 cells display a greatly enhanced ability to form rapidly growing and invasive tumors compared with oncogenes expressed in other cell lines. NCM-1 cells were isolated from rat embryos and immortalized by transduction with a v-myc-containing replication-deficient retrovirus. 22 Although v-myc expression itself can be transforming, 48 this is not the case in NCM-1 cells because of their ability to differentiate, 22 and because they do not grow in soft agar, or form tumors in vivo. This is confirmed by our qPCR array analysis, which showed very low, barely detectable levels of myc in CONT NCM-1 cells as well as in the DIgTrkB NCM-1 cells. DIgTrkB NCM-1 cells form large tumors prompting Scale bar in (g) is equivalent to 1 mm and also applies to (h). Scale bar in (d) is equivalent to 100 mm.
euthanasia of mice 2 weeks after a subcutaneous injection of one million cells; when only 100 cells are injected, 100% of the mice form tumors by 21 days. Similar in vivo tumor growth was seen in a v-myc-immortalized rat fibroblast cell line expressing oncogenic BCR-ABL; however, this study injected 50% more cells to initiate tumorigenesis. 49 In another study, expression of the oncogene BCL2 in a rat L6 myoblast cell line expressing v-myc-caused tumors formed only after 10 weeks. 50 Recently, Schulte et al. 51 found JoMa1 neural crest progenitor cells (which are maintained in an undifferentiated state by inducible c-myc expression) can be transformed by an oncogenic variant of the ALKF1174L, and two out of six mice were able to form tumors in vivo that were lethal to the mouse by 48 days, following injection of 20 million cells. Thus, DIgTrkB is considerably more oncogenic in vivo than ALKF1174L. Not only did DIgTrkB NCM-1 tumors grow at a rapid pace, but they are also highly invasive. In one mouse, tumor cell invasion of the spine, caused spinal cord compression, and bilateral paralysis. This spinal cord invasion mimics human neuroblastoma, where the cancer can extend into spinal foramina causing nerve root and spinal cord compression in patients with paraspinal tumors. [52] [53] [54] In total, 5% of all neuroblastoma patients will present with signs related to cord impingement. It is not clear whether the TrkB signaling is directly responsible for this transformed phenotype or if TrkB is acting through upregulation of MYCN. Regardless, it is likely that these changes result in alterations of other genes that contribute to the aggressive phenotype of these tumors. MYCN amplification is the most consistent genetic alteration seen in poor prognosis neuroblastoma 55 and as evidence that MYCN is sufficient to drive neuroblastoma formation, the TH-MYCN transgenic mouse forms neuroblastoma-like tumors spontaneously. 56 However, the TH-MYCN-derived tumors are slower growing and more confined than the tumors we observed from DIgTrkB NCM-1 cells. In addition, TH-MYCN tumors highly express BDNF, but lack TrkB expression (DeWitt and Nishi, unpublished data). JoMa1 neural crest cells overexpressing MYCN also form highly variable, slow-growing tumors with mice surviving anywhere from 43-123 days. 51 Thus, the activation of TrkB signaling can enhance the aggressive behavior of tumors. Interestingly, constitutive TrkB signaling in NCM-1 cells induces a 21-fold upregulation of MYCN mRNA in DIgTrkB NCM-1 cells that is comparable with the 20-to 80-fold MYCN levels observed in neuroblastoma tumors and cell lines. 57 Our studies suggest that one plausible initiating event in forming aggressive neuroblastoma is the failure of TrkB expression to be downregulated early in development. Our previous studies showed that TrkB is transiently expressed during a developmental period when sympathoblasts are commencing differentiation and hence likely downregulating MYCN. However, when BDNF is introduced, these TrkB positive progenitors are stimulated to divide again. 7 Thus, aberrant activation of TrkB could trigger upregulation of MYCN together with the activation of additional pathways that contribute to a highly aggressive, carcinogenic phenotype. This underscores the importance of the development of therapies targeting TrkB signaling, such as lestaurtinib (CEP-701). 58 
MATERIALS AND METHODS Constructs
Using a full-length rat trkb (WT trkb) construct generously provided by Dr Moses Chao, New York University, NY, USA, we used site-directed mutagenesis to convert a single base at base pair 1814 into a pst1 site. Both immunoglobulin-like domains could then be removed by pst1 (New England Biolabs, Ipswich, MA, USA) digestion due to another pst1 site at base pair 1233. For HEK293 experiments, DIgtrkb and WT trkb were cloned into pcDNA3.1 (Invitrogen, San Diego, CA, USA). For PC12 experiments, DIgtrkb was cloned into an inducible vector (pTRE-tight, Clontech, Mountain View, CA, USA) and transfected into an rTTa-expressing PC12 Tet-on cell line (Clontech). For NCM-1 experiments, DIgtrkb was cloned into a piggyBAC transposon-transposase vector (pmGENIE-3) containing a DsRed tag and hygromycin selection gene. NCM-1 cells were transfected with a GFP-expressing control piggyBAC vector (pmGENIE-3) to establish a control cell line for in vivo experiments.
Cell Culture
Cells were grown at 37 1C in 5% CO 2 . HEK293 and NCM-1 cells were maintained in 10% (v/v) fetal bovine serum, 20 U/ml penicillin, 20 mg/ml streptomycin, 2 mM L-glutamine, and 6 mg/ml glucose in modified L15CO2. Serum for PC12 cells was 5% fetal bovine serum and 5% heat-inactivated horse serum.
Transfections HEK293 and PC12 cells were transfected using JetPEI (Polyplus transfection, Illkirch, France). Stably transfected HEK293 cells were established by G418 (Sigma, St Louis, MO, USA) selection. NCM-1 cells were transfected using X-tremeGENE 9 (Roche, Indianapolis, IN, USA) and stable cells were established by hygromycin (Sigma) selection.
Westerns
Cells were seeded at 250 000 per well in six-well plates. For HEK293 experiments cells were serum starved for 24 h, treated with, or without BDNF (100 ng/ml, R&D Systems, Minneapolis, MN, USA) for 1 h and then collected for SDS-PAGE by direct lysis into 100 ml 1Â SDS sample buffer þ b-mercaptoethanol. Samples were run on an 8% polyacrylamide gel, then transferred to a nitrocellulose membrane (Osmonics, Inc., Minnetonka, MN, USA) overnight at 4 1C at 30 volts (Hoefer Scientific Instruments, San Francisco, CA, USA). Blots were incubated with primary antibodies overnight at 4 1C followed by appropriate secondary antibodies for 1 h at room temperature. Primary antibodies used were: goat anti-TrkB (1:1000, R&D Systems); rabbit anti-p-Erk1/2 (1:500, Cell Signaling, Boston, MA, USA); goat anti-b actin (1:1000, Santa Cruz, Santa Cruz, CA, USA); rabbit anti-Phospho-Histone H3 (1:500, Cell Signaling); and mouse anti-Cyclin D1 (1:1000; Cell Signaling). Secondary antibodies used were donkey anti-goat 700 (Rockland, Gilbertsville, PA, USA); donkey anti-rabbit 800 (Rockland) and donkey anti-mouse 800 (Rockland) all at 1:10 000. Blots were analyzed using an Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE, USA).
PC12 neurite outgrowth
PC12 cells were plated on poly-D-lysine (0.5 mg/ml, Sigma)-and laminin (0.02 mg/ml, purified in the Nishi lab from EHS tumors grown subcutaneously in C57Bl6 mice)-coated coverslips at 50 000 cells per well. The day after plating, cells were transfected with either an inducible GFP or the inducible DIgtrkb construct and allowed to recover for 48 h prior to treatment with doxycline (1 mg/ml, Sigma) and 7s NGF (1 mg/ml, Alomone, Jerusalem, Israel). Coverslips were fixed 30 min in Zamboni's fixative (4% (w/v) paraformaldehyde, 15% (v/v) picric acid in 0.1 M sodium phosphate buffer, pH 7.4) and processed for immunocytochemistry as previously described. 7 Primary antibodies were: goat anti-TrkB (1:1000, R&D Systems); chicken anti-GFP (1:1000, Aves, Tigard, OR, USA). Secondary antibodies were: donkey anti-goat alexa 488 (1:1000, Invitrogen) and goat anti-chicken alexa 488 (1:1000, Invitrogen). A Nikon (Melville, NY, USA) Eclipse E800 microscope connected to a computer equipped with StereoInvestigator software (MBF Bioscience, Williston, VT, USA) was used to count neurite-positive PC12 cells (at least one process of a length at least twice the diameter of the cell soma).
Calcein AM
NCM-1 cells were plated on poly-D-lysine-coated 96-well plates at 200 cells per well in 100ml of media and viability assessed using 2 mM calcein AM (Molecular Probes, Eugene, OR, USA) with a FLUOstar Galaxy (BMG, Cary, NC, USA) fluorescent microplate reader. Each condition was replicated in a minimum of 8 wells on the same plate. For K252a (Merck, Darmstadt, Germany) and c-Met inhibitor (SU11274, Merck) experiments, inhibitors (50 nM and 1 mm, respectively) were added at the time of plating. suspended in 0.35% agar were plated on top of the base layer at 1000 cells per well. Cells were fed by adding 0.5 ml of media to the top of each well every 3 days. After 10 days, cultures were fixed overnight with 4% paraformaldehyde in PBS, then stained with 0.005% crystal violet.
Anoikis assay
To quantify anoikis, medium was collected 3 days after cultures achieved confluence and the number of live cells growing in the media was quantified by trypan blue (0.08%, Sigma) exclusion and a hemocytometer.
Migration and invasion
The 'donut assay' for migration and invasion was used as described. 28 10 000 cells were plated on poly-D-lysine and laminin-coated coverslips in a 10-ml volume. Initial images were acquired through a 2 Â PlanApo objective on a Nikon Eclipse TE-2000E inverted microscope. A second set of images acquired at 24 h were compared and analyzed using the default settings of a custom-written ImageJ macro. Area migrated/invaded was quantified by measuring the area between the outer bound of the farthest migrating/invading cells after 24 h, and the bound of the cells directly after gasket removal.
RNA extraction and qPCR array
Cells were grown to confluence in six-well plates, lysed directly into TRI Reagent (Molecular Research Center, Cincinnati, OH, USA), and RNA was isolated using the manufacturer's protocol. RNA quality and genomic DNA contamination were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Reverse transcription and Cancer Pathways qPCRarray plate (SABiosciences, Valencia, CA, USA) analysis were performed at the UVM Vermont Cancer Center DNA Analysis Facility using RT2 First Strand kit (SABiosciences). Data shown in Tables 1 and 2 represent the mean of three independently isolated RNA samples from three different wells of a six-well plate for each cell line.
MYCN expression transcription levels were evaluated by reverse transcription of 1 mg of RNA transcribed to cDNA using (Superscript III, Invitrogen) and subsequent Taqman-based qPCR (ABI).
In vivo
Mice were housed in an NIH and AALAC approved animal facility at UVM and treated following an approved IACUC protocol. Cells were injected subcutaneously into flanks of NOD-SCID mice at 10 6 cells per mouse in 200 ml of matrigel (BD Biosciences, San Jose, CA, USA). Four mice were injected per cell line. When tumors became palpable, tumor growth was quantified every other day at first, and then daily when it became apparent that TrkB tumors were fast growing. Tumor volume was estimated from length and width measurements using the established formula: v ¼ 1.58(p/ 6)(L Â W)^(3/2). 59 To examine the lower limits of the tumorigenic potential of DIgTrkB NCM-1 cells, 100 cells in 200 ml of matrigel were injected into three NOD-SCID mice, which were monitored for tumor formation.
